TRAIL (TNF-Related Apoptosis-Inducing Ligand), encoded by the TNFSF10 gene, is a member of the tumor necrosis factor (TNF) superfamily that plays complex roles in cell death, immune surveillance, and neuroinflammation. Originally identified for its ability to induce apoptosis in transformed and cancer cells while sparing normal cells, TRAIL has emerged as a critical regulator of neuronal survival and death in the context of neurodegenerative diseases. In the central nervous system, TRAIL is expressed by neurons, astrocytes, microglia, and oligodendrocytes, where it participates in both physiological processes like synaptic pruning and pathological mechanisms driving neurodegeneration.
The unique feature of TRAIL signaling lies in its receptor system: TRAIL binds to four membrane-bound receptors with distinct signaling properties. Two death receptors (DR4/TRAIL-R1 and DR5/TRAIL-R2) propagate pro-apoptotic signals through caspase-8 activation, while two decoy receptors (DcR1/TRAIL-R3 and DcR2/TRAIL-R4) sequester TRAIL and prevent cell death. This elegant system allows precise control over cell fate decisions in the healthy brain, but dysregulation of TRAIL signaling contributes to the pathogenesis of Alzheimer's disease, Parkinson's disease, multiple sclerosis, and amyotrophic lateral sclerosis.
| TRAIL — TNF-Related Apoptosis-Inducing Ligand | |
|---|---|
| Gene Symbol | TRAIL (TNFSF10) |
| Full Name | TNF Superfamily Member 10 (TNF-Related Apoptosis-Inducing Ligand) |
| Chromosomal Location | 3q26.1 |
| NCBI Gene ID | [8743](https://www.ncbi.nlm.nih.gov/gene/8743) |
| Ensembl ID | ENSG00000117586 |
| UniProt ID | [P50591](https://www.uniprot.org/uniprot/P50591) |
| Protein Family | TNF superfamily, Type II transmembrane proteins |
| Alternative Names | Apo-2L, TL2A, CD253 |
| Associated Diseases | Alzheimer's Disease, Parkinson's Disease, ALS, Multiple Sclerosis |
The TNFSF10 gene spans approximately 17 kilobases on the reverse strand of chromosome 3 (3q26.1). The gene consists of six exons encoding a type II transmembrane protein of 281 amino acids. Unlike typical TNF family members, TRAIL is expressed as a membrane-bound protein that can be proteolytically cleaved to form a soluble ligand, allowing both cell-associated and secreted signaling.
TRAIL is synthesized as a Type II transmembrane protein with the following structural features:
N-terminal Cytoplasmic Domain: The short N-terminus (approximately 16 amino acids) faces the cytoplasm and contains no obvious signaling motifs.
Transmembrane Helix: A hydrophobic transmembrane domain (approximately 21 amino acids) anchors the protein in the cell membrane.
C-terminal Extracellular Domain: The bulk of the protein (approximately 224 amino acids) extends extracellularly and contains:
Trimeric Structure: Like other TNF family members, TRAIL functions as a trimer. The trimeric structure is essential for high-affinity receptor binding and signaling.
Several TRAIL splice variants have been identified:
TRAIL signals through a complex receptor system with four membrane-bound receptors:
| Receptor | Type | Signaling | Expression Pattern |
|---|---|---|---|
| DR4 (TRAIL-R1) | Death receptor | Pro-apoptotic | Wide, including neurons |
| DR5 (TRAIL-R2) | Death receptor | Pro-apoptotic | High in brain |
| DcR1 (TRAIL-R3) | Decoy receptor | Anti-apoptotic | Limited in brain |
| DcR2 (TRAIL-R4) | Decoy receptor | Anti-apoptotic | Some neurons |
Additionally, osteoprogerin (OPG) can bind TRAIL with low affinity, serving as a soluble decoy receptor.
Death Receptor Signaling (DR4/DR5):
TRAIL binding → Receptor trimerization → Death domain formation
↓
FADD recruitment → Caspase-8 activation
↓
Direct pathway: Caspase-3/7 activation → Apoptosis
↓
Mitochondrial pathway: Bid cleavage → MOMP → Caspase-9 → Caspase-3 → Apoptosis
Decoy Receptor Signaling (DcR1/DcR2):
Beyond apoptosis, TRAIL can trigger non-apoptotic signaling:
Within the brain, TRAIL is expressed by multiple cell types:
Neurons: Both central and peripheral neurons express TRAIL:
Glial Cells:
TRAIL expression in the brain is not uniform:
| Brain Region | TRAIL Expression | Receptor Expression |
|---|---|---|
| Cerebral cortex | Moderate | High DR5 |
| Hippocampus | High | High DR4/DR5 |
| Substantia nigra | Moderate | High DR5 |
| Cerebellum | Moderate | Moderate |
| Spinal cord | Low-moderate | High DR5 (motor neurons) |
TRAIL expression is dynamically regulated:
Transcriptional Control:
Post-translational Regulation:
In Alzheimer's disease, TRAIL contributes to neurodegeneration through multiple mechanisms:
Amyloid-beta-induced TRAIL Expression: Exposure of neurons and astrocytes to amyloid-beta leads to:
Synaptic Dysfunction: TRAIL signaling affects synaptic function:
Neuroinflammation: TRAIL amplifies neuroinflammatory responses:
Therapeutic Implications: Targeting TRAIL in AD:
In Parkinson's disease, TRAIL plays a critical role in dopaminergic neuron death:
Dopaminergic Neuron Vulnerability: Substantia nigra dopaminergic neurons are particularly sensitive to TRAIL:
Mechanisms of Neurodegeneration:
Therapeutic Targeting:
In amyotrophic lateral sclerosis, TRAIL contributes to motor neuron death:
Motor Neuron Sensitivity:
Non-Cell Autonomous Toxicity:
Therapeutic Approaches:
In multiple sclerosis, TRAIL has complex roles:
Oligodendrocyte Death:
Immune Cell Regulation:
Therapeutic Potential:
TRAIL triggers apoptosis in neurons through the extrinsic pathway:
Caspase-8 Activation: Binding to DR4/DR5 leads to:
Executioner Caspase Activation:
Mitochondrial Amplification:
TRAIL amplifies neuroinflammatory responses:
Microglial Activation:
Cytokine Cascade:
Blood-Brain Barrier: TRAIL affects BBB integrity:
TRAIL influences synaptic physiology:
Synaptic Pruning: Physiological role in development:
Synaptic Dysfunction:
Multiple therapeutic strategies are being developed:
TRAIL Neutralization:
Decoy Receptor Agonists:
Downstream Inhibition:
Biomarker Potential: TRAIL levels may serve as biomarkers:
Challenges:
TRAIL interacts with alpha-synuclein pathology:
TRAIL and amyloid-beta have bidirectional relationship:
TRAIL is both regulator and regulator of neuroinflammation:
Ongoing research areas include:
Recent advances include:
Research employs various models:
Several mouse models have been developed to study TRAIL function in the nervous system:
TRAIL Knockout Mice: Complete loss of TRAIL results in:
TRAIL Transgenic Models: Overexpression of TRAIL leads to:
Disease Models:
New approaches are advancing the field:
The structural basis of TRAIL signaling has been elucidated through X-ray crystallography:
TRAIL-Receptor Complexes:
Death Receptor Activation:
Decoy Receptor Mechanisms:
TRAIL undergoes conformational changes upon receptor binding:
During brain development, TRAIL serves important functions:
Synaptic Pruning:
Neuronal Survival:
Immune Surveillance:
TRAIL expression changes during development:
TRAIL and its receptors may serve as biomarkers:
Cerebrospinal Fluid:
Blood:
Multiple approaches are being developed:
TRAIL Neutralization:
Receptor Modulation:
Downstream Inhibition:
Several clinical approaches have been tested:
| Approach | Status | Indication |
|---|---|---|
| AMG 655 (soluble DR5) | Completed | Cancer |
| Apo2L/TRAIL | Completed | Cancer |
| Caspase inhibitors | Phase 2 | Liver disease |
| DR5 agonists | Phase 1 | Neurodegeneration |
TRAIL interacts with other TNF superfamily members:
FasL/Fas:
TNF-α:
TWEAK:
Alpha-synuclein:
Amyloid-beta:
Tau:
ER Stress:
Oxidative Stress:
TRAIL (TNFSF10) is a multifunctional TNF superfamily member with critical roles in neuronal survival, neuroinflammation, and synaptic function. Its unique receptor system allows precise control over cell fate decisions in the healthy brain, but dysregulation of TRAIL signaling contributes to the pathogenesis of multiple neurodegenerative diseases including Alzheimer's disease, Parkinson's disease, ALS, and multiple sclerosis. Understanding the complex biology of TRAIL in the central nervous system offers opportunities for developing novel therapeutic strategies to protect vulnerable neuronal populations and modulate neuroinflammatory responses.
The discovery of TRAIL in the mid-1990s generated excitement for its potential in cancer therapy due to its tumor-selective apoptosis-inducing activity. Subsequent research revealed its important physiological functions in immune surveillance and tissue homeostasis. In the nervous system, TRAIL was initially studied in the context of tumor cell death, but investigators soon recognized its broader roles in neurodegeneration, neuroinflammation, and synaptic plasticity. The complexity of TRAIL signaling — with its dual death and decoy receptor system — provides both challenges and opportunities for therapeutic targeting.